Cite

    Huang, J., Li, C., Song, Y., Fan, X., You, L., Tan, L., Xiao, L., Li, Q., Ruan, G., Hu, S., Cui, W., Li, Z., Ni, L., Chen, C., Woo, A., Xiao, R., & Wang, D. (2018). aDRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure. Cell discovery, 4(1), 1–13. http://access.bl.uk/ark:/81055/vdc_100084819501.0x00013b